KNSA vs MA · P/E 53, rev $677.6M vs P/E 38, rev $17.68B
Kiniksa Pharmaceuticals Ltd (KNSA) versus Mastercard Inc (MA) — a side-by-side from cached financials, not a winner call.
Kiniksa Pharmaceuticals Ltd (KNSA) is a drug manufacturers - specialty & generic company listed on US.
Mastercard Inc (MA) is a credit services company listed on US. It is led by Michael Miebach.
Latest reported KNSA revenue for 2025-12-31 was $677.6M. Net income was $59.0M. Revenue was up 60.1% from 2024-12-31 to 2025-12-31. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.
Latest reported MA revenue for 2026-06-30 was $17.68B. Net income was $8.27B. MA currently screens at market cap $515.12B and trailing P/E 38.4.
KNSA currently screens at market cap $3.73B and trailing P/E 53.2. MA currently screens at market cap $515.12B and trailing P/E 38.4.
Not investment advice. Open the KNSA and MA stock pages for the full models.
Not investment advice.